Date: 2025-04-03

The Withings ScanWatch plays a pivotal role in cardiology trials, particularly in the context of enhancing the detection and management of atrial fibrillation (AF), the most prevalent form of cardiac arrhythmia [1]. By participating in comparative studies alongside other leading cardiac wearable devices, the Withings ScanWatch is subjected to rigorous testing against the gold standard of physician-interpreted 12-lead ECGs. The primary purpose of including the Withings ScanWatch in such trials is to validate its accuracy and reliability in identifying AF episodes in a diverse real-world patient cohort [1]. This not only underscores the device's potential in early AF detection but also highlights its significance in preventive cardiology, offering a non-invasive, continuous monitoring solution that could revolutionize AF screening and management strategies within clinical and everyday settings [1].